Merit Medical Acquires Biolife Delaware, L.L.C.

Core Viewpoint - Merit Medical Systems, Inc. has acquired Biolife Delaware, L.L.C. for approximately $120 million, enhancing its hemostatic solutions portfolio and positioning the company for growth in a $350 million global market opportunity [1][2][4]. Financial Summary - The acquisition is expected to contribute revenue of $10 to $11 million from May 20, 2025, to December 31, 2025, and is projected to generate approximately $18 million in annualized revenue starting in fiscal year 2026 [6][7]. - The acquired assets generated approximately $15 million in revenue for the twelve-month period ending December 31, 2024 [6]. - The acquisition is anticipated to be slightly dilutive to Merit's non-GAAP profitability in 2025 but accretive to non-GAAP gross margin and operating margin in 2025 and to non-GAAP net income and earnings per share in 2026 [8]. Updated Financial Guidance - Merit has updated its full-year 2025 financial guidance to reflect the impact of the Biolife acquisition, projecting net sales between $1.480 billion and $1.501 billion, representing a year-over-year growth of 9% to 11% [10]. - The cardiovascular segment is expected to generate net sales of $1.407 billion to $1.426 billion, while the endoscopy segment is projected to achieve net sales of $73 million to $75 million [10]. - Non-GAAP earnings per share are projected to be between $3.28 and $3.41, reflecting a slight decrease compared to prior guidance [10]. Product and Market Impact - Biolife's StatSeal and WoundSeal products are designed to improve hemostasis and are expected to complement Merit's existing product offerings across various clinical applications [3][4]. - The acquisition is aligned with Merit's strategy to provide comprehensive solutions to healthcare providers and enhance patient care [4][6].